Sanofi's valuations attractive: Should you invest?

Monday, 3 May 2021, 03:00:00
Chronic therapeutic treatments contribute around 63% of Sanofi India’s domestic sales and the same is now under several restrictions due to the Covid-19 related disturbances. The company’s growth opportunities should improve once the situation stabilises and patients start coming back to the hospitals for treatment of other diseases. Despite short-term challenges, Sanofi continues to do well and was able to beat the street expectations with its results for the first quarter of 2021. While its q-o-q revenue remained stable, its y-o-y revenue declined by 8%. However, this decline was due to the divestment of its Ankleshwar plant and discontinuation of a few products to Zentiva. Its adjusted revenue growth is placed at 9% y-o-y. Its qo-q gross margin which declined mostly because of the increased contribution from low margin imports was offset by operational cost savings. Its q-o-q ebitda and net profit grew by 13% and 19% respectively. 82342643 !function(){“use strict”;window.addEventListener(“message”,(function(a){if(void 0!==a.data[“datawrapper-height”])for(var e in a.data[“datawrapper-height”]){var t=document.getElementById(“datawrapper-chart-“+e)||document.querySelector(“iframe[src*='”+e+”‘]”);t&&(t.style.height=a.data[“datawrapper-height”][e]+”px”)}}))}(); Despite being a mid-cap pharma company, analysts continue to impose their faith in Sanofi India due to its long term growth outlook.
— Economic Times India

Sanofi Shares Rise On Q1 Sales Boosted By Dupixent Franchise; Plans To Restart Haemophilia Study With Fitusiran

Wednesday, 28 April 2021, 19:27:23
Sanofi SA (NASDAQ: SNY ) stock climbed after its Q1 earnings beat earnings expectations and stuck to its full-year guidance, as well as reported progress on its delayed COVID-19 vaccine efforts. Earnings: Overall sales increased by 2.4%, attributed mainly to Dupixent’s success, with vaccines also contributing with a 5.3% rise in sales to €915 million. The Regeneron Pharmaceuticals Inc (NASDAQ: REGN )-partnered drug pulled in more than €1 billion worldwide for a year-over-year increase of 45.6% at the common exchange rate. Dupixent also scored a spot on China’s coveted National Reimbursement Drug List in March, marking the official launch of Dupixent in one of the world’s largest markets. Two of Sanofi’s … Full story available on Benzinga.com
— Benzinga

Eczema treatment and vaccines lift Sanofi first quarter results

Wednesday, 28 April 2021, 09:15:49
https://www.investing.com/news/stock-market-news/eczema-treatment-and-vaccines-lift-sanofi-first-quarter-results-2487626
— Investing.com

Sanofi Steps In For Fill-Finish 200M Doses Of Moderna's COVID-19 Vaccine

Monday, 26 April 2021, 15:18:32
As the demand for mRNA-based COVID-19 vaccines persists, Sanofi SA (NASDAQ: SNY ) has entered an agreement with Moderna Inc (NASDAQ: MRNA ) to manufacture its COVID-19 vaccine in the U.S. The agreement marks the third different company Sanofi has paired with to manufacture a COVID-19 vaccine since their effort to develop a shot faced significant setbacks. Sanofi will perform fill-and-finish at its Ridgefield facility in New Jersey to complete up to 200 million doses of the vaccine beginning in September. The financial details of the arrangement were not … Full story available on Benzinga.com
— Benzinga

Sanofi-AstraZeneca's Nirsevimab Hits Primary Endpoint Goal In Late-Stage RSV Disease In Infants

Monday, 26 April 2021, 12:16:21
Sanofi SA (NASDAQ: SNY ) and AstraZeneca Plc’s (NASDAQ: AZN ) monoclonal antibody (mAb) nirsevimab has reached its primary endpoint in a Phase 3 trial, demonstrating protection against respiratory syncytial virus disease (RSV) in healthy infants. The data comes earlier than anticipated; regulatory submissions for all-infant indications are expected to begin in 2022. Nirsevimab, an investigational extended half-life … Full story available on Benzinga.com
— Benzinga